These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21142696)

  • 1. Heat-stable ritonavir tablets: a new formulation of a pharmacokinetic enhancer for HIV.
    Sherman EM; Steinberg JG
    Expert Opin Pharmacother; 2011 Jan; 12(1):141-8. PubMed ID: 21142696
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saquinavir/Ritonavir: its evolution and current treatment role.
    O'Brien WA
    AIDS Read; 2006 Jan; 16(1):38-44; discussion 43. PubMed ID: 16433471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-HIV agents. Lopinavir and ritonavir (Kaletra) tablets get tested.
    TreatmentUpdate; 2008 Mar; 20(2):5-6. PubMed ID: 18661644
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to the comparison of generic ritonavir (Ritomune, Cipla) and lopinavir/ritonavir tablets (Lopimune, Cipla) and the Abbott brand (Norvir soft-gel capsules and Kaletra tablets).
    Chachad S; Gogtay J; Malhotra G; Purandare S
    J Pharm Sci; 2010 Feb; 99(2):572-3; author reply 574. PubMed ID: 19718766
    [No Abstract]   [Full Text] [Related]  

  • 5. Heat-stable Norvir tablet provides similar drug levels to capsule.
    AIDS Patient Care STDS; 2008 Sep; 22(9):761-2. PubMed ID: 18802977
    [No Abstract]   [Full Text] [Related]  

  • 6. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
    Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
    Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Acknowledgement of human bioequivalency of matrix's lopinavir-ritonavir formulation to Kaletra, comment to article on Bioavailability of generic ritonavir and lopinavir/ritonavir tablet products in a dog model, by Garren et al.
    Rackley RJ
    J Pharm Sci; 2010 Feb; 99(2):568-71; author reply 574. PubMed ID: 19746411
    [No Abstract]   [Full Text] [Related]  

  • 8. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
    Calza L; Manfredi R; Trapani F; Salvadori C; Colangeli V; Borderi M; Grossi G; Motta R; Viale P
    Scand J Infect Dis; 2012 May; 44(5):381-7. PubMed ID: 22263609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.
    Garvey L; Latch N; Erlwein OW; Mackie NE; Walsh J; Scullard G; McClure MO; Dickinson L; Back D; Winston A
    Antivir Ther; 2010; 15(2):213-8. PubMed ID: 20386076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic interactions between ritonavir-boosted darunavir and NNRTIs: a report of 3 cases.
    Rawizza HE; Sax PE
    AIDS Read; 2008 Sep; 18(9):466-72, 478-9. PubMed ID: 18828231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lopinavir + ritonavir tablets: new formulation. More convenient, but minimal evaluation.
    Prescrire Int; 2007 Aug; 16(90):148. PubMed ID: 17724839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Norvir soft-gel capsule formulation approved by FDA.
    Gaylord G
    Posit Living; 1999 Aug; 8(7):11. PubMed ID: 12492076
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
    Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
    AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients.
    Zeldin RK; Petruschke RA
    J Antimicrob Chemother; 2004 Jan; 53(1):4-9. PubMed ID: 14657084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability of ritonavir soft capsule formulation in patients with and without a refrigerator at home in Côte d'Ivoire.
    Danel C; Peytavin G; Moh R; Konan R; Gabillard D; Anglaret X
    Int J STD AIDS; 2006 Nov; 17(11):784-5. PubMed ID: 17062190
    [No Abstract]   [Full Text] [Related]  

  • 16. Lopinavir/ritonavir: a protease inhibitor combination.
    Med Lett Drugs Ther; 2001 Jan; 43(1095):1-2. PubMed ID: 11151088
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.
    Martínez E; Larrousse M; Llibre JM; Gutiérrez F; Saumoy M; Antela A; Knobel H; Murillas J; Berenguer J; Pich J; Pérez I; Gatell JM;
    AIDS; 2010 Jul; 24(11):1697-707. PubMed ID: 20467288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Saquinavir/low-dose ritonavir: its use in HIV infection.
    Johnson M; Peters B
    AIDS Rev; 2003; 5(1):44-51. PubMed ID: 12875107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ritonavir-boosted protease inhibitors: impact of ritonavir on toxicities in treatment-experienced patients.
    Sension M; Piliero PJ
    J Assoc Nurses AIDS Care; 2007; 18(1):36-47. PubMed ID: 17338984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.